<div id="readability-page-1"><p>Shares of PepGen, Inc. (NASDAQ:PEPG - Get Free Report) have received an average recommendation of &#34;Moderate Buy&#34; from the six analysts that are currently  covering the stock, MarketBeat Ratings reports. One investment analyst  has rated the stock with a sell rating and five have given a buy rating to  the company. The average 12 month target price among analysts that have covered the stock in the last year is $11.80.</p><ul><li>Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher</li></ul><p>Several equities research analysts have commented on PEPG shares. Wedbush decreased their target price on shares of PepGen from $9.00 to $5.00 and set an &#34;outperform&#34; rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of PepGen in a research report on Thursday, January 22nd. Oppenheimer started coverage on PepGen in a research note on Wednesday, February 25th. They set an &#34;outperform&#34; rating and a $15.00 price target for the company. Finally, Guggenheim lifted their price target on PepGen from $6.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, February 18th.</p><p><b>Get Our Latest Research Report on PEPG</b></p><h2>PepGen Stock Performance</h2><ul><li>PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data</li></ul><p>Shares of NASDAQ PEPG opened at $1.64 on Monday. The firm has a market capitalization of $113.35 million, a P/E ratio of -0.68 and a beta of 2.34. PepGen has a one year low of $1.01 and a one year high of $7.80. The company's fifty day moving average is $4.93 and its two-hundred day moving average is $5.20. </p><p>PepGen (NASDAQ:PEPG - Get Free Report) last issued its earnings results on Wednesday, March 4th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.13.  On average, sell-side analysts forecast that  PepGen will post -2.73 earnings per share for the current fiscal year. </p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds and other institutional investors have recently made changes to their positions in the company. Monashee Investment Management LLC acquired a new position in shares of  PepGen during the 3rd quarter worth $1,386,000.  Boxer Capital Management LLC acquired a new position in shares of  PepGen during the 3rd quarter worth $1,155,000.  Commodore Capital LP acquired a new position in shares of  PepGen during the 3rd quarter worth $10,891,000.  Fifth Lane Capital LP acquired a new position in shares of  PepGen during the 3rd quarter worth $323,000.  Finally, Squarepoint Ops LLC acquired a new position in shares of  PepGen during the 4th quarter worth $203,000. Institutional investors and hedge funds own  58.01% of the company's stock. </p><h2>About PepGen</h2> (Get Free Report)<p>PepGen, Inc <span>NASDAQ: PEPG<span></span></span> is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration. </p><p>The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).</p><h2>Further Reading</h2><ul><li>Five stocks we like better than PepGen</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEVQRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEVQRw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in PepGen Right Now?</h2><p>Before you consider PepGen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.</p><p>While PepGen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PEPG

SBIO

IBBQ

ARKG

LABU

<p>Shares of PepGen, Inc. (NASDAQ:PEPG) have received an average recommendation of "Moderate Buy" from six analysts. One analyst rated it as a sell, while five rated it as a buy. The average 12-month target price is $11.80. Recent price targets include a decrease from $9.00 to $5.00 by Wedbush and an increase to $7.00 by Guggenheim. PepGen's stock opened at $1.64, with a market cap of $113.35 million. Institutional investors own 58.01% of the company, which focuses on gene editing therapies for rare genetic diseases.</p>

Market Beat

PepGen

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages